Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In Gout (STING)

NCT06956885 PHASE2 NOT_YET_RECRUITING

According to international recommendations, urate lowering therapy (ULT), mainly the xanthine oxidase inhibitors (XOIs) allopurinol and febuxostat, should be prescribed lifelong in gout patients. However, this recommendation comes up against very poor adherence to ULT, since around half of patients stop their treatment at 5 years. Moreover, there is uncertainty about the cardiovascular tolerance of febuxostat taken over the long term. Finally, although XOIs are generally well tolerated, they can cause side effects and require regular biological monitoring. The hypothesis is that the risk of flares following withdrawal of ULT is very low in gout patients when urate store is depleted and repeated ultrasounds (US) do not demonstrate the reappearance of urate deposits.

Details

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	PHASE2
Status	NOT_YET_RECRUITING
Enrolment	450
Start date	Thu May 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed May 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Gout Chronic

Interventions

• Discontibuation of oral ULT
• Maintenance of ULT